|
|
| | Lanifibranor Basic information |
| Product Name: | Lanifibranor | | Synonyms: | IVA337;IVA-337;Lanifibranor;CPD1537;IVA-337;4-(1-(1,3-Benzothiazol-6-ylsulfonyl)-5-chloro-indol-2-yl)butanoic Acid;Lanifibranor (IVA337);5-chloro-1-[(6-benzothiazolyl)sulfonyl]-1H-indole-2-butanoic acid;4-(1-(benzo[d]thiazol-6-ylsulfonyl)-5-chloro-1H-indol-2-yl)butanoic acid | | CAS: | 927961-18-0 | | MF: | C19H15ClN2O4S2 | | MW: | 434.92 | | EINECS: | 691-126-0 | | Product Categories: | | | Mol File: | 927961-18-0.mol |  |
| | Lanifibranor Chemical Properties |
| Boiling point | 690.9±65.0 °C(Predicted) | | density | 1.56±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF:50.0(Max Conc. mg/mL);114.97(Max Conc. mM)
DMSO:79.0(Max Conc. mg/mL);181.65(Max Conc. mM)
DMSO:PBS (pH 7.2) (1:4):0.2(Max Conc. mg/mL);0.46(Max Conc. mM)
Ethanol:0.2(Max Conc. mg/mL);0.46(Max Conc. mM) | | form | A crystalline solid | | pka | 4.69±0.10(Predicted) | | color | White to light brown |
| | Lanifibranor Usage And Synthesis |
| Uses | Lanifibranor, a new antifibrotic clinical candidate, acting as a pan peroxisome proliferator-activated receptor (PPAR) agonist. |
| | Lanifibranor Preparation Products And Raw materials |
|